No recent analyst price targets found for APLM.
Latest News for APLM
Apollomics Reports First Half 2025 Financial Results
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for APLM.
Senate Trading
No Senate trades found for APLM.
U.S. House Trading
No House trades found for APLM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.